Tumorschmerztherapie in Deutschland: Ergebnisse und Analysen einer Befragung von Ärzten

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • R. Sabatowski - , Universität zu Köln (Autor:in)
  • E. R. Arens - , Johnson & Johnson (Autor:in)
  • I. Waap - , Johnson & Johnson (Autor:in)
  • L. Radbruch - , Universität zu Köln (Autor:in)

Abstract

The German regulations for opioid prescriptions have been changed in February 1998. The regulations have been made much more easier and should therefore have improved the pain management in Germany. We investigated the knowledge of the WHO analgesic ladder and how they have been followed in a nation-wide survey among physicians not specialised in pain management. Only 9% of the questionnaires were returned. Although the majority of the physicians (93%) reported knowledge about the WHO recommendations for the treatment of cancer pain, more than 15% of the participating physicians rated transdermal fentanyl as a weak opioid or even as a non-opioid. A negative pain management index in 15% of the patients gave evidence of poor quality in pain management. The majority of patients (84%) did not receive immediate release analgesics for the treatment of breakthrough pain. Continuous medical education is still necessary before a further alleviation of regulations will help to reduce the undertreatment of patients suffering from cancer pain in Germany.

Details

OriginalspracheDeutsch
Seiten (von - bis)241-247
Seitenumfang7
FachzeitschriftSchmerz
Jahrgang15
Ausgabenummer4
PublikationsstatusVeröffentlicht - 2001
Peer-Review-StatusJa
Extern publiziertJa

Externe IDs

PubMed 11810362

Schlagworte

Ziele für nachhaltige Entwicklung

Schlagwörter

  • Cancer pain management, Opioids, Pain management index, WHO-step-ladder